The effect of cGMP (cyclic GMP) dependent protein kinase 1-β (PKG1-β) and cGMP analogues on transcriptional activity and replication of human immunodeficiency virus type 1 (HIV-1) was investigated. Transfection of PKG1β expression plasmid increased expression from an HIV-1 LTRreporter as well as from an infectious HIV-1 molecular clone, pNL4-3. Treatment of HIV-1 AD8infected monocyte derived macrophages (MDMs) with cGMP agonists and cGMP antagonists caused respectively increased and decreased virus replication. These findings provide evidence that cGMP and PKG serve to regulate HIV-1 infection in human cells.
Findings
Previously nitric oxide (NO) was postulated to have a negative effect on HIV-1 replication through a cGMP-independent route [1] . However, it was not characterized as to how this cGMP-independent effect manifested mechanistically. On the other hand, it is well-accepted that a major intracellular signaling pathway for NO is through a cytosolic-guanylate cyclase linked cGMP-dependent protein kinase, PKG, pathway [2] . cGMP/PKG has been shown to activate abundantly both CREB [3] and NF-κB [4, 5] . Interestingly, to our knowledge, no systematic investigation of cGMP/PKG's activity on the HIV-1 LTR has been reported to date.
To address how cGMP/PKG might influence HIV-1 LTRdirected expression, we transfected HeLa cells with a LTRluciferase reporter with or without a Tat-plasmid [6-9]and assayed for expression with or without simultaneously co-transfecting a PKG1β-expression vector [10]-( Figure 1 ). We found that PKG1β-alone activated reporter expression by approximately 4 fold (also see Figure 2B ) while Tat-alone activated expression by >45 fold ( Figure  1A ). Co-transfection of LTR-luciferase + Tat + PKG1β activated expression cumulatively to >175 fold ( Figure 1A) . These results are consistent with PKG1β inducing LTRdriven expression whether in the absence or presence of Tat.
To verify more physiologically the above LTR-reporter assay, we next checked the effect of PKG1β on an HIV-1 infectious molecular clone, pNL 4-3 ( Figure 1B ). Here, increasing amounts of PKG1β-plasmid were transfected into cells with a constant level of pNL 4-3. Viral proteins expressed from the HIV-1 molecular clone were then measured. Using HIV-specific hyper-immune sera in Western blots, we observed that PKG1β increased pNL 4-3 expression in a dose dependent manner ( Figure 1B , lanes 2 -6). To investigate whether the intact function of PKG1β was needed for this activity, we created two lossof-function PKG1β deletion mutants (Figure 2A ). Both deletion mutants were unable to activate either a LTR- reporter ( Figure 2B ) or an HIV-1 infectious molecular clone ( Figure 2C ).
PKG1β activates expression from the HIV-1 LTR
Optimal PKG activity is dependent on activation by cGMP [11] . While over expression of exogenously transfected PKG offered significantly measureable effects (Figures 1,  2) , we wished to understand next how cell endogenous PKG might act mechanistically in response to cGMP treatment. Elsewhere, it was reported that NF-κB p65, p52, and p50 are substrate proteins activated by PKG-mediated phosphorylation. Because expression of the HIV-1 LTR is regulated by NF-κB [12, 13] , we asked if cGMP activated NF-κB in our experimental.
To assess if NF-κB was activated by cGMP, we assayed for enhanced nuclear localization of NF-κB protein p65, which is one measure of activation [14, 15] . We treated cells with a cGMP agonist, 8-pCPT-cGMP, and compared results to cells treated with a known NF-κB activator, tumor necrosis factor alpha, TNFα. When cytosolic and nuclear p65 proteins were assayed, we observed that 8-pCPT-cGMP behaved quantitatively very similarly to TNFα in inducing increased NF-κB p65-translocation into the nucleus ( Figure 3A) . This result supports that PKGactivation of HIV-1 (Figures 1, 2) acts through an NF-κBmediated process. To confirm that PKG1β can directly activate NF-κβ activity, we transfected a NF-κβ luciferase reporter into cells with or without a co-transfected PKG1β
Intact PKG1 β is required for activation of gene expression Figure 2 Intact PKG1 β is required for activation of gene expression. A) Schematic representations are shown of full length PKG1β (pCMV-PKG1β FLAG) and two deletion mutants, pCMV-PKG1β 1-417 FLAG and pCMV-PKG1β ∆349FLAG. Transfected cell lysates (right panel) were analyzed by Western blotting using anti-FLAG antibody for expression. B) Full length PKG1β, but not its deletion mutants, activated LTR-luciferase expression. HeLa cells were transfected with the indicated plasmids. C) Full PKG1β, but not its deletion mutants, activated pNL4-3-expression. Plasmids were transfected into HeLa cells as indicated. Cand N-terminus deletions of PKG1β resulted in loss of activity. Nuclear and cytoplasmic fractions were collected and assayed for NF-κβ p65 by Western blotting. Both TNFα and 8-pCPT-cGMP were found to increase nuclear NF-κβ p65 while commensurately decreasing cytoplasmic NF-κβ p65. Western blotting for tubulin controlled for subcellular fractionations. Quantifications of relative distributions of NF-κβ p65 are shown at bottom. B) PKG1β increases expression of NF-κB dependent luciferase. HeLa cells were transfected with NF-κB luciferase reporter plasmid in the presence or absence of co-transfected PKG1β expression plasmid. Cells were harvested 24 hours post-transfection, and cell lysates were assayed for luciferase activity as indicated. expression plasmid ( Figure 3B ). Results from this assay showed that NF-κβ-dependent luciferase activity was indeed elevated by PKG1β.
Treatment of HeLa cells with cGMP agonist, 8-(4-chlorophenylthio)guanosine 3'.5'-cyclic monophosphate (8-pCPT-cGMP), increased NF-κβ p65 in the nucleus
A more direct verification of cGMP/PKG's role in HIV-1 replication can be established using chemical agonists and antagonists of this pathway seeking for effects on viral infection. Because the NO/cGMP signaling pathway has been reported to function potently in cells of macrophage lineage, we performed infection of monocyte derived macrophages (MDMs) using HIV-1 strain AD8 [16, 17] . MDMs infected with AD8 were treated individually with three different drugs. We employed two cGMP agonists (8-pCPT-cGMP, and Sp-8-pCPT-cGMP) and one cGMP antagonist (Rp-8-pCPT-cGMPs) and monitored their impact on HIV-1 replication. Informatively, in two separate experiments, both agonist drugs increased virus replication over control-treated infection, while the cGMPantagonist drug decreased (or did not affect) virus replication ( Figure 4 ).
Here, we report evidence that both in the absence and presence of Tat the cGMP/PKG pathway can serve to modulate HIV-1 expression/replication. Understanding how HIV-1 LTR expression is affected by ambient cellular pathways [18] [19] [20] may help to address potential approaches for treating latent HIV-1 infection [21] . The current findings may be important because cGMP is a ubiquitous second messenger that affects multiple cellular pathways in most, if not all, cells. Accordingly, cGMP-influenced pathways are likely to interdigitate with some of the signaling routes utilized by HIV-1 in infected cells [22] . Additionally, because many cGMP chemical agonists and antagonists are available [23, 24] , practical chemotherapeutic interventions in these pathways (if they should be useful for anti-viral purposes) could be amenable.
Effect of cGMP analogues on pAD8 replication in monocyte derived macrophages (MDM's) Figure 4 Effect of cGMP analogues on pAD8 replication in monocyte derived macrophages (MDM's). MDM's were cultured in RPMI medium containing 10% human serum, infected 5-7 days post culture with HIV-1 AD8 virus, and cells were treated at time of infection with cGMP agonists -8-pCPT-cGMP and Sp-8-pCPT-cGMP or cGMP antagonist (Rp-8-pCPT-cGMPs). Culture supernatants were collected every third day and assayed for virus production by RT assays. cGMP agonists increased virus production from AD8 infected MDM's while cGMP antagonists suppressed virus production.
